Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 11,424,970 | 11,520,500 | 10,666,100 | 9,466,402 | 10,387,570 |
| Cost of Goods | 3,515,934 | 3,043,558 | 2,891,574 | 2,439,652 | 3,268,568 |
| Gross Profit | 7,909,035 | 8,476,943 | 7,774,528 | 7,026,750 | 7,118,998 |
| Operating Expenses | 6,438,117 | 4,982,396 | 5,073,182 | 4,236,350 | 6,193,828 |
| Operating Income | 1,471,853 | 3,495,105 | 2,701,919 | 2,791,052 | 925,737 |
| Interest Expense | 249,520 | 225,099 | 245,750 | 204,039 | 221,912 |
| Other Income | 51,620 | 40,436 | 64,108 | 68,013 | 51,080 |
| Pre-tax Income | 1,273,953 | 3,310,442 | 2,520,277 | 2,655,026 | 754,905 |
| Income Tax | 300,778 | 420,545 | 321,880 | 423,192 | 84,956 |
| Net Income Continuous | 973,176 | 2,889,898 | 2,198,398 | 2,231,834 | 669,950 |
| Minority Interests | 121,507 | 176,575 | 271,127 | 186,406 | 110,798 |
| Net Income | $851,668 | $2,713,323 | $1,927,271 | $2,045,428 | $559,152 |
| EPS Basic Total Ops | 0.43 | 1.35 | 0.95 | 1.00 | 0.27 |
| EPS Basic Continuous Ops | 0.49 | 1.43 | 1.08 | 1.09 | 0.33 |
| EPS Diluted Total Ops | 0.41 | 1.32 | 0.94 | 0.99 | 0.26 |
| EPS Diluted Continuous Ops | 0.46 | 1.41 | 1.07 | 1.09 | 0.31 |
| EPS Diluted Before Non-Recurring Items | 0.68 | 1.48 | 1.23 | 1.13 | 0.59 |
| EBITDA(a) | $857,035 | $4,514,233 | $4,312,510 | $3,827,621 | $1,403,679 |